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Abstract
Objectives—To evaluate the association between inflammation and heart failure (HF) risk in
older adults.
Background—Inflammation is associated with HF risk factors and also directly affects
myocardial function.
Methods—The association of baseline serum concentrations of interleukin-6 (IL-6), tumor
necrosis factor alpha (TNF-α), and C-reactive protein (CRP) with incident HF was assessed with
Cox models among 2610 older persons without prevalent HF enrolled in the Health ABC Study
(age, 73.6±2.9 years; 48.3% men; 59.6% white).
Results—During follow-up (median, 9.4 years), 311 participants (11.9%) developed HF. In
models controlling for clinical characteristics, ankle-arm index, and incident coronary heart
disease, doubling of IL-6, TNF-α, and CRP concentrations was associated with 29% (95% CI, 13
to 47%; P<.001), 46% (95% CI, 17 to 84%; P=.001), and 9% (95% CI, -1 to 24%; P=.087)
increase in HF risk, respectively. In models including all three markers, IL-6 and TNF- α, but not
CRP, remained significant. These associations were similar across sex and race and persisted in
models accounting for death as a competing event. Post-HF ejection fraction was available in 239
(76.8%) cases; inflammatory markers had stronger association with HF with preserved ejection
fraction. Repeat IL-6 and CRP determinations at 1-year follow-up did not provide incremental
information. Addition of IL-6 to the clinical Health ABC HF model improved model
discrimination (C index from 0.717 to 0.734; P=.001) and fit (decreased Bayes information
criterion by 17.8; P<.001).
Conclusions—Inflammatory markers are associated with HF risk among older adults and may
improve HF risk stratification.
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Inflammatory markers, including interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α),
and C-reactive protein (CRP), are elevated in patients with heart failure (HF) and are
associated with outcomes regardless of etiology (1–6). Inflammatory markers are also
elevated in individuals with asymptomatic left ventricular systolic and diastolic dysfunction
(7–9), and experimental studies have suggested that IL-6 and TNF-α are associated with left
ventricular remodeling, fetal gene expression, myocyte hypertrophy, and myocyte apoptosis
(10). These observations raise the possibility that inflammation may be related to a
heightened risk for HF, and previous studies have indeed suggested such an association (11–
13). However, the number of incident HF events in these studies was small precluding an
opportunity to assess for possible differential association across major demographic groups
and adequately control for important predictors of HF including incident coronary events.
Finally, the incremental value of inflammatory markers for HF risk determination was not
assessed in these studies.
We recently developed and validated a prediction model for incident HF in the elderly, the
Health ABC HF model (14), based on nine routinely available variables including age,
history of coronary heart disease (CHD), smoking, systolic blood pressure, heart rate, and
serum concentrations of fasting glucose, creatinine, and albumin. Most of these risk factors
have been associated with inflammation. For example, the association of inflammation with
CHD and subclinical atherosclerosis is well documented (15,16), as is the association
between inflammation and diabetes mellitus (17). Systemic low-grade inflammation has
been reported in smokers (18). Both inflammation and oxidative stress have been correlated
with chronic kidney disease (19). Similar associations have been reported for hypertension
and hypoalbuminemia (20,21). Thus, beyond the direct effects on myocardial cells,
inflammation may also drive HF risk through the creation of a biologic milieu that
predisposes individuals to HF.
In this study, we assessed the association between baseline levels of inflammatory markers
and risk for HF among the elderly participants of the Health, Aging, and Body Composition
(Health ABC) Study in the total cohort and in predefined subgroups of interest, as well as
the possible incremental value of these markers for incident HF prediction. In addition, we
assessed the impact of multiple inflammatory marker elevation and the incremental value of
serial biomarker measurements for incident HF prediction.
METHODS
Study Population
Study population for this investigation included participants in the Health ABC Study, a
population-based cohort of 3075 community-dwelling men and women aged 70 to 79 years
at inception. To be eligible, participants had to report no difficulty in walking mile or
climbing 10 stairs without resting. Participants were identified from a random sample of
white Medicare beneficiaries and all age-eligible black community residents in designated
zip codes areas surrounding Pittsburgh and Memphis. Exclusion criteria included difficulties
with activities of daily living, obvious cognitive impairment, inability to communicate with
the interviewer, or intention of moving within 3 years. All participants gave written
informed consent; the Institutional Review Boards at both study sites approved the protocol.
Baseline data were collected in 1997–1998 and these results represent the outcomes during
ten years of follow-up. The presence of cardiovascular disease at baseline was based on ICD
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9-CM codes, as reported by Medicare and Medicaid Services for the years 1995–1998, self-
reported history, and the use of selected drugs (22). Participants with HF or missing data on
HF at baseline (n=140) were excluded from this analysis. Of the 2935 participants without
HF at baseline, 2612 (89.0%) had available IL-6, TNF-α, and CRP serum concentrations.
Two participants were excluded because of extreme outlier values of TNF-α; the remaining
2610 participants were included in this study.
Serum Biomarker Measurements
In the Health ABC Study, concentrations of biomarkers were obtained from frozen stored
serum or plasma collected at baseline after an overnight fast. Samples were obtained in the
morning and after processing, the specimens were frozen at −70°C, and shipped to the Core
Laboratory at the University of Vermont. Cytokines were measured in duplicate by ELISA.
The detectable limit for IL-6 was 0.10 pg/mL and for TNF-α 0.18 pg/mL. Serum
concentrations of CRP were also measured in duplicate by ELISA on the basis of purified
protein and polyclonal anti-CRP antibodies. The CRP assay was standardized according to
World Health Organization First International Reference Standard with a sensitivity of 0.08
μg/mL. Blind duplicate analyses (n=150) for IL-6, CRP, and TNF-α showed inter-assay
coefficients of variation of 10.3%, 8.0%, and 15.8%, respectively.
Repeat determinations of IL-6 and CRP serum levels at year 2 visit (i.e., at first 1-year
follow-up) were available in 2372 (90.9%) and 2370 (90.8%) of the 2610 participants with
inflammatory marker levels at baseline. Repeat determinations were not available for TNF-
α. The year 2 samples of IL-6 and CRP were analyzed in a different laboratory (Wake Forest
University) than the baseline samples (University of Vermont) and calibrated based on 150
samples that were analyzed both at Wake Forest University and University of Vermont. The
intra-class correlation coefficient for the calibrated samples was 0.93 for IL-6 and 0.89 for
CRP.
Study Definitions
Race was self-defined by the participant. Hypertension was defined as self-reported history
of physician diagnosis accompanied by use of antihypertensive medications. Diabetes was
defined as self-reported history of diabetes or use of antidiabetic medications. Smoking
status was classified as current, past (≥100 lifetime cigarettes), or never. Left ventricular
hypertrophy was diagnosed based on electrocardiogram using the following voltage criteria;
R amplitude >26 mm in either V5 or V6, or R amplitude >20 mm in any of leads I, II, III,
aVF, or R amplitude >12 mm in lead aVL or R amplitude in V5 or V6 plus S amplitude in
V1 >35 mm. Definite CHD was defined as (1) history of coronary artery bypass graft or
percutaneous coronary angioplasty; or (2) electrocardiographic evidence of myocardial
infarction; or (3) history of myocardial infarction or angina accompanied by use of
antianginal medications. Probable CHD was defined as self-reported history of myocardial
infarction or angina without use of antianginal medications. Cerebrovascular disease was
defined as history of stroke or transient ischemic attack or carotid endarterectomy.
Peripheral arterial disease was defined as history of claudication or lower extremity bypass
or angioplasty. Methods of assessment of ankle-arm index in Health ABC have been
previously published (23).
Study Outcomes
All participants were asked to report any hospitalizations and every 6 months were asked
direct questions to elicit information about interim events. All first admissions with an
overnight stay confirmed to be related to HF by local adjudicators were classified as incident
HF. Adjudication criteria for HF required, in addition to a physician diagnosis of HF, (1)
medical record documentation of symptoms (e.g. shortness of breath, fatigue, orthopnea,
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paroxysmal nocturnal dyspnea) and physical signs (e.g. edema, pulmonary rales, gallop
rhythm,); (2) supporting clinical findings such as evidence of pulmonary edema on chest
radiography or evidence supporting HF on echocardiography; and (3) medical therapy for
HF, including at least a diuretic and a vasodilator and/or digitalis. Information on left
ventricular ejection fraction (EF) post-HF development was abstracted from any imaging
report in the medical record. Incident CHD was defined as hospitalization for myocardial
infarction, angina pectoris, or elective coronary revascularization, either surgical or
percutaneous.
Statistical Analysis
The proportion of variance of inflammatory markers explained by baseline characteristics
was assessed using multiple regression. The association of inflammatory markers with HF
risk was assessed with Cox proportional hazards models. Inflammatory marker
concentrations were log transformed prior to regression analyses because of skewed
distributions. We opted for log2 transform (i.e. logarithm with basis 2) to facilitate
communication, because the hazard ratio per log2-transformed increase denotes the increase
in hazard associated with doubling of the original value. The proportionality assumption in
Cox models was assessed with the Schoenfeld residuals.
In multivariable models, we controlled for (1) baseline characteristics, including use of
antihypertensive and anti-inflammatory medications (entered as a binary indicator variable
for each class), and (2) ankle-arm index, as a measure of subclinical atherosclerosis, and
time-varying incident CHD evaluated at 1-year intervals, in nested models. We repeated
these analyses in subgroups defined by the presence or absence of any atherosclerotic
disease (definite or probable CHD, cerebrovascular disease, or peripheral arterial disease).
Finally, we repeated these analyses with death as a competing event, using the competing
risks model (proportional subhazards model) proposed by Fine and Gray (24).
In secondary analyses, we assessed the association between inflammatory markers and risk
for HF with reduced (≤45%) vs. preserved (>45%) left ventricular EF. Although there is no
universally accepted cutoff point for EF, an EF>45% is considered to represent preserved
systolic function by most investigators and has also been used in recent trials (25,26). For
this analysis, only new HF cases with documented left ventricular EF were considered as
events in separate (reduced vs. preserved) Cox models. In addition, we assessed the effect of
combined elevations of multiple inflammatory markers on HF risk. For this analysis, we
empirically divided biomarker values using the cohort median. Finally, we evaluated the
prognostic value of changes in IL-6 and CRP at 1-year follow-up for future incident HF
among the 2370 participants who had repeat IL-6 and CRP determinations and were still
free of HF at 1-year follow-up.
The incremental value of inflammatory markers for HF risk prediction over the Health ABC
HF model (14), was assessed with the Harrell’s C index for survival models and the change
in Bayes information criterion, a likelihood-based measure of model fit that penalizes for the
number of variables in the model (27,28). For calculation of the Bayes information criterion,
we applied the Volinsky and Raftery modification for censored data (28), and corresponding
P values for improvement were calculated according to Wagenmakers (29).
For multivariable models, missing values of covariates were imputed using the multiple
imputation by chained equations procedure as introduced by van Buuren et al (30,31).
Parameter estimates were obtained by combining 5 imputed datasets using the method
described by Barnard and Rubin to account for possible error in missing value analysis (32).
A two-sided p<0.05 was accepted as statistically significant for all analyses. Analyses were
performed with STATA versions10 and 11 (StataCorp, College Station, TX).
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RESULTS
Baseline Participant Characteristics and Inflammatory Marker Distribution
Table 1 shows the baseline participant characteristics and Table 2 shows the distribution of
biomarkers overall and by HF development. The mean age of participants was 73.6±2.9
years; 48.3% were men and 59.6% were white. During a median follow-up of 9.4 years
(interquartile range [IQR], 7.0–9.4), 311 participants (11.9%) developed HF (15.1 cases per
1000 person-years) and 790 participants (30.3%) died (annual mortality, 3.7%).
Table 3 presents the correlation between the inflammatory markers and baseline participant
characteristics. Multiple statistically significant correlations were detected; however, these
were modest. In multiple regression analyses, baseline characteristics were able to explain
16.2%, 27.6%, and 16.2% of the variance of log-transformed IL-6, TNF-a, and CRP,
respectively.
Inflammatory Markers and Incident Heart Failure
All inflammatory markers were associated with HF risk in unadjusted analyses; HR per
doubling of levels was 1.61 (95% CI, 1.43–1.80; P<.001) for IL-6, 1.83 (95% CI, 1.51–2.21;
P<.001) for TNF-α, and 1.25 (95% CI, 1.14–1.36; P<.001) for CRP. The proportional
hazards assumption was valid for all three markers (P value for the χ2 test of Schoenfeld
residuals was .55, .73, and .45, for IL-6, TNF-α, and CRP, respectively) and association with
HF risk was similar across sex and race (P values for interaction terms >.15). In models
controlling for all baseline characteristics, the association of IL-6 and TNF-α with HF risk
remained significant, whereas that of CRP was attenuated (Table 4). Adding baseline ankle-
arm index (as a measure of baseline subclinical atherosclerosis) and incident CHD as a time-
varying covariate in the model did not materially affect the estimates; doubling of
concentrations of IL-6, TNF-α, and CRP was associated with 29% (95% CI, 13 to 47%),
46% (95% CI, 17 to 84%), and 9% (95% CI, −1 to 24%) increase in HF risk, respectively, in
fully adjusted models (Table 4). When all markers were entered simultaneously in adjusted
models, only IL-6 and TNF-α, but not CRP, remained independently associated with HF
risk.
In subgroups defined by the presence or absence of any atherosclerotic (CHD, cerebro-
vascular or peripheral) disease at baseline, IL-6 and TNF-α were associated with incident
HF risk in both subgroups. Notably, TNF-α appeared to be a stronger predictor of HF among
participants with prevalent atherosclerotic disease, whereas IL-6 was a stronger predictor
among participants without atherosclerotic disease at baseline. Considering that this is a
post-hoc analysis based on a posteriori definition, these results need to be interpreted with
caution.
When death was accounted for as a competing event using the Fine and Gray proportional
subhazards models, IL-6 and TNF-α were still strongly associated with incident HF risk and
both provided complementary information in models with all markers included (Table 5),
whereas CRP was not associated with incident HF in competing risks models.
Incident Heart Failure with Preserved and Reduced EF
Information on post-HF left ventricular EF was available for 239 of 311 (76.8%) incident
HF cases. Median EF was 43% (IQR, 27 to 55%). When only cases with preserved EF were
considered (105 of 239; 43.9%), IL-6 (HR per doubling, 1.49; 95% CI, 1.19–1.86; P<.001)
and TNF-α (HR per doubling, 1.81; 95% CI, 1.23–2.68; P=.003) were strongly associated
with HF risk in models controlling for baseline characteristics; association was less robust
for CRP (HR per doubling, 1.15; 95% CI, 0.96–1.36; P=.12). When all three markers were
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included in the model, IL-6 (HR per doubling, 1.40; 95% CI, 1.09–1.80; P=.008) and TNF-α
(HR per doubling, 1.60; 95% CI, 1.08–2.38; P=.020) were independently associated with HF
risk, whereas CRP was not (HR per doubling, 1.01; 95% CI; 0.84–1.22; P=.90). The
associations of IL-6 and TNF-α with incident HF did not materially change in models
additionally controlling for ankle-arm index at baseline and incident CHD as time-varying
covariate (data not shown). When only HF cases with reduced EF (134 of 239; 56.1%) were
considered, inflammatory markers were marginally associated with HF risk; HR per
doubling of levels was 1.21 (95% CI, 0.99–1.48; P=.067) for IL-6, 1.36 (95% CI, 0.96–1.93;
P=.081) for TNF-α, and 1.09 (95% CI, 0.93–1.27; P=.28) for CRP in models controlling for
baseline characteristics. This association was further attenuated in models that additionally
controlled for ankle-arm index at baseline and incident CHD (data not shown).
Multiple Inflammatory Marker Elevations and Incident Heart Failure Risk
Compared with participants who had concentrations below the cohort median for all three
biomarkers (n=515), those with one (n=795), two (n=776), or three (n=524) biomarkers
elevated at baseline had increased risk for HF in unadjusted analyses (HR, 1.45; 95% CI,
0.97–2.17; P=.074; HR, 2.37; 95% CI, 1.61–3.48; P<.001; and HR, 3.20; 95% CI, 2.16–
4.74; P<.001, respectively; P for trend <.001). The increased risk persisted for those with
two or three biomarkers elevated in models adjusted for baseline characteristics (HR, 1.26;
95% CI, 0.83–1.90; P=.27; HR, 1.65; 95% CI, 1.10–2.47; P=.014; and HR, 1.76; 95% CI,
1.14–2.70; P=.010, for participants with one, two, or three biomarkers elevated,
respectively; P for trend =.003) (Figure 1). These results did not change when ankle-arm
index and incident CHD was included in the model (data not shown).
Serial Biomarkers and Incident Heart Failure Risk
Among the 2370 participants who had repeat determinations of IL-6 and CRP at year 2 and
were still free from HF, median increase in IL-6 and CRP levels from year 1 was 0.30 pg/
mL (IQR, −0.39 to 1.25 pg/mL) and 0.51 μg/mL (IQR, −1.07 to 2.08 μg/mL), respectively.
Repeat IL-6 and CRP levels were still associated with future HF risk (HR per doubling,
1.21; 95% CI, 1.09–1.36; P=.001 and 1.12; 95% CI, 1.03–1.21; P=.006, respectively).
However, the change in IL-6 or CRP from baseline to 1-year follow-up was not associated
with HF risk (both P>.5).
Incremental Value for Incident Heart Failure Prediction
We have previously developed a HF risk prediction model, the Health ABC HF model (14).
Addition of all 3 inflammatory markers to this clinical model increased the C index from
0.717 (95% CI, 0.686–0.747) to 0.737 (95% CI, 0.709–0.765), P=.001 for the comparison,
and improved model fit as assessed with the Bayes information criterion (decreased by 10.9
units; P=.004). The improvement was mainly due to IL-6; adding only IL-6 to clinical
predictors improved C index to 0.734 (95% CI, 0.706–0.763; P=.001 for the comparison),
and improved Bayes information criterion by 17.8 units (P<.001) because of a more
parsimonious model.
DISCUSSION
In this study, we validate earlier observations suggesting that inflammatory cytokines are
associated with incident HF risk. In our study, IL-6 and TNF-α were independently
associated with HF development whereas CRP demonstrated a weaker association. These
findings were consistent in both sexes, in blacks and whites, and persisted in models
controlling for clinical characteristics, ankle-arm index, and incident coronary events. In
addition, both IL-6 and TNF-α were associated with incident HF in models with death as a
competing risk. The association between inflammatory markers and HF risk was stronger for
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HF with preserved as opposed to reduced EF; this however needs cautious interpretation as
post-HF EF was not uniformly assessed in the Health ABC Study. Finally, serial
determinations of IL-6 and CRP added little information. Using the clinical Health ABC HF
model as baseline, we found that addition of IL-6 in the model improved model
performance. These observations underscore the relation between inflammation and HF risk,
and may have screening and prevention implications.
The rate of incident HF in our study was similar to a recent cohort study reporting on HF
incidence among older adults (33). Importantly, these rates are lower compared to
administrative data (34,35). Varying rates of incident HF have also been reported by the
Framingham Heart Study, the Cardiovascular Health Study, and from the Olmsted County,
Minnesota (36–38). These differences are likely related to different age, racial mix,
geographic variation etc but also to varying diagnostic criteria. Regardless of the precise
estimate, a high incidence rate, worsening profile with aging, and either stagnant or
increasing incidence rates over the last decades are common findings across these studies.
Inflammation may contribute to HF development in multiple ways. Enhanced inflammatory
state may create a milieu that increases risk for HF since many HF risk factors are associated
with inflammation. Indeed, in our analysis, all risk factors for HF in the Health ABC cohort
(14), albeit modestly, were correlated with inflammatory marker levels. However, our data
suggest that inflammation may also have a more direct role in HF development since the
association between inflammation and HF persisted despite controlling for known HF risk
factors. Previous data support our findings. The Framingham investigators have shown that
there was a 60% (with TNF-α) to 68% (with IL-6) increase in HF risk per tertile increase in
cytokine concentration (11). Two other studies have suggested a similar association (12,13);
however, all three studies had small number of HF cases (n<100). In this respect, the large
number of incident HF cases, and longer follow-up in our study (median, 9.4 years) allowed
us to control for multiple risk factors and incident CHD, and perform important subgroup
analyses.
Previous reports support a potential direct role for inflammation in HF development. Both
IL-6 and TNF-α affect cardiomyocyte contractility (39–41). These cytokines also influence
left ventricular remodeling and hypertrophy (42–45). Interestingly, unlike the previous
studies (11–13), CRP levels had a weak association with HF risk in our study, and were not
associated with HF in models including IL-6 and TNF-α. This is likely related to the
rigorous controlling for confounders in our study. Although CRP may promote left
ventricular remodeling by stimulating IL-6 production (46), there are no data to suggest a
direct association between CRP levels and left ventricular remodeling. Moreover, elevated
CRP levels may reflect increased hepatic synthesis under the influence of elevated IL-6
levels and thus represent a “distal” phenomenon secondary to a more “proximal” primary
excess production of IL-6 (47,48).
Several additional observations from our study merit attention. First, our findings were
consistent across sex and in white and black participants. Second, inflammatory marker
levels had a strong association with HF with preserved EF. This association is plausible
because inflammation has been linked with diastolic dysfunction in patients with
hypertension (49) and CHD (8,9), and inhibition of inflammatory pathways prevents
diastolic dysfunction in experimental diabetic cardiomyopathy (50,51). This finding has
important implications as HF is primarily a disease of the elderly and many of these
individuals develop HF with preserved EF. However, cautious interpretation is needed
because post-HF left ventricular function was not systematically assessed in the Health ABC
Study and the corresponding findings are therefore subject to possible selection bias.
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What are the implications of these findings? First, it provides pathophysiologic insights into
HF development and raises the possibility that inflammation might be a target for prevention
interventions in selected individuals. For example, agents with anti-inflammatory properties
e.g. statins might be able to modulate HF risk among individuals with elevated levels of
inflammatory biomarkers who are at high risk for developing heart failure. If proven, this
might be especially important for HF with preserved EF, for which no effective therapy
currently exists. Indeed, in the statin trials for secondary prevention, incident HF reduction
has been reported (52,53), and statins have been shown to prevent ventricular remodeling in
experimental studies (54,55). However, whether targeted administration of statins would
attenuate HF risk among high-risk individuals is speculative and needs further study. Also, if
IL-6 assays were to be developed and commercially available, it is possible that adding IL-6
to clinical predictors might facilitate earlier identification of high-risk individuals and
implementation of preventive strategies.
Our study has several limitations. Diagnosis of HF was based on HF hospitalization.
Because some participants may have developed HF without requiring hospitalization, HF
rates are likely underestimated. Echocardiography was not performed at baseline in the
Health ABC Study and thus participants with asymptomatic structural heart abnormalities
may have been included in the analysis. It may be argued, therefore, that the risk associated
with elevated inflammatory marker levels is merely because of inclusion of participants with
yet undetected HF at baseline. However, the association with HF risk was consistent over
time as shown by the proportionality tests, i.e. hazards did not converge over time. Because
HF is unlikely to remain undiagnosed for several years, we contend that the observed
association cannot be ascribed merely to undetected HF at baseline. Also, left ventricular
function during hospitalization for HF was not prospectively assessed in the Health ABC
Study and information on left ventricular EF was based on chart review in a subset (76.8%)
of participants with incident HF; thus, the corresponding results should be interpreted with
caution.
In conclusion, in this study we demonstrate a significant association between inflammatory
markers and risk for incident HF among older persons. These findings were consistent
across sex and race, and persisted after controlling for HF risk factors and incident CHD.
Multiple biomarker elevations at baseline were associated with pronounced risk for HF.
Inclusion of IL-6 in a clinical model for HF risk prediction significantly improved the
predictive properties of the model. The practical implications of our findings, including
screening individuals for HF risk determination or targeting inflammation to reduce HF risk,
need further study.
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CHD Coronary heart disease
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HR Hazard ratio
IL-6 Interleukin-6
IQR Interquartile range
sHR Subhazard ratio
TNF-α Tumor necrosis factor alpha
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Figure 1. Heart Failure Rates According to the Number of Elevated Inflammatory Markers at
Baseline
Adjusted Kaplan-Meier plots illustrating cumulative heart failure incidence among Health
ABC Study participants according to the number of elevated inflammatory markers
(interleukin-6, tumor necrosis factor alpha, or C-reactive protein) at baseline. Adjustment
model included all baseline characteristics as described in Table 1.
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Table 1
Baseline Participant Characteristics (N=2610)
Characteristic Value
Age, years 73.6 ± 2.9
Male sex, % 48.3
Black race, % 40.4
Body mass index, kg/m2 27.3 ± 4.7
Waist/thigh circumference ratio 1.95 ± 0.21
Smoking, %
 Current 10.5
 Past 44.6
Alcohol consumption, %
 Never 49.5
 <1 drink/week 21.5
 1–7 drinks/week 21.9
 >7 drinks/week 7.0
Diabetes mellitus, % 14.8
Hypertension, % 53.1
Coronary heart disease, %
 Definite 16.2
 Probable 3.3
Cerebrovascular disease, % 7.7
Peripheral arterial disease, % 4.8
Left ventricular hypertrophy, % 12.1
Systolic blood pressure, mg/dl 136 ± 21
Diastolic blood pressure, mg/dl 71 ± 12
Heart rate, bpm 65 ± 11
Fasting glucose, mg/dl* 94 (87, 105)
Albumin, gm/dl 4.0 ± 0.3
Creatinine, mg/dl* 1.0 (0.9, 1.2)
Total cholesterol, mg/dl 203 ± 38
Low density lipoprotein, mg/dl 122 ± 34
High density lipoprotein, mg/dl 54 ± 17
Triglycerides, mg/dl* 118 (88, 161)
Medications
 Beta blockers, % 12.2
 Angiotensin converting enzyme inhibitors, % 14.3
 Calcium channel blockers, % 22.2
 Thiazide diuretics, % 17.6
 Other antihypertensive, % 8.5
 Statins, % 12.5
 Steroids, % 2.2
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Characteristic Value
 Non-steroid anti-inflammatory agents, %† 51.4
*
Value expressed as median (interquartile range) because of highly skewed distributions
†
Including salicylates
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Table 2
Inflammatory Markers According to Incident Heart Failure Development
Marker Total cohort (N=2610) Participants without incidentHF (N=2299)
Participants with incident HF
(N=311) P value
Interleukin-6, pg/mL* 1.80 (1.23, 2.76) 1.75 (1.20, 2.67) 2.31 (1.56, 3.43) <.001
Tumor necrosis factor α, pg/mL* 3.14 (2.41, 4.06) 3.10 (2.40, 3.96) 3.49 (2.58, 4.76) <.001
C-reactive protein, μg/mL* 1.64 (0.99, 3.04) 1.60 (0.97, 2.97) 1.94 (1.18, 3.81) <.001
*
Values are expressed as median (interquartile range) because of highly skewed distributions and compared with the Mann-Whitney test
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